A case of insulin antibody-mediated insulin resistance in type 2 diabetes treated by glucocorticoid
| Autor: | Mouna Mnif, Fatma Mnif, Nabila Rekik, Ben Salah Dhoha, Mouna Elleuch, Mohamed Abid |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
insulin glucocorticoids business.industry Insulin medicine.medical_treatment lcsh:R lcsh:Medicine Type 2 diabetes medicine.disease_cause medicine.disease Autoimmunity Titer Insulin resistance Endocrinology Internal medicine insulin resistance diabetes mellitus medicine Prednisolone insulin antibody business Glucocorticoid medicine.drug Glycemic |
| Zdroj: | PAMJ Clinical Medicine, Vol 1, Iss 40 (2019) |
| ISSN: | 2707-2797 |
| Popis: | The syndromes of severe insulin resistance (IR), although rare, are very interesting and clinically important. It causes a deterioration of the glycemic control, despite the very high dose of insulin. One of the rarest etiologies is autoimmunity especially the production of insulin autoantibody. We report the case of a 61-year-old woman with a history of type 2 diabetes for 10 years. She has reported a deterioration of her glycemic control despite an increase in the dose of insulin up to 200U/day (d). The clinical examination was without particularity. There was no history of drug intake. A high titer of insulin antibodies was detected in the serum 77.6%. Prednisolone was administered with a dose of 0,5mg/Kg/d for 1month. The dosage was tapered 5mg at 15 days intervals until 5mg/d. Insulin requirement decreased by 66% and glycemic control was reached. The treatment of antibody-mediated IR is not standardized; corticosteroid therapy often gives good results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|